FDA Grants Early Approval To Daraxonrasib Pancreatic Cancer Drug With Survival Benefit
5d
Breaking
4
The FDA granted expedited approval Wednesday, Aug. 26, 2026, to daraxonrasib, marketed as Rasonque, for advanced metastatic pancreatic cancer, clearing a new option for patients whose disease no longer responds to other treatments. NPR
